Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1244197.RABc_AJ4kFXMTD7S9XxDBylAkLTDAPljYThiDkdiM53gg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1244197.RABc_AJ4kFXMTD7S9XxDBylAkLTDAPljYThiDkdiM53gg130_assertion type Assertion NP1244197.RABc_AJ4kFXMTD7S9XxDBylAkLTDAPljYThiDkdiM53gg130_head.
- NP1244197.RABc_AJ4kFXMTD7S9XxDBylAkLTDAPljYThiDkdiM53gg130_assertion description "[The US Food and Drug Administration-approved BRAF inhibitors, vemurafenib and dabrafenib, have demonstrated superior efficacy in patients with BRAF-mutant melanomas but have limited efficacy in BRAF-mutant colorectal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244197.RABc_AJ4kFXMTD7S9XxDBylAkLTDAPljYThiDkdiM53gg130_provenance.
- NP1244197.RABc_AJ4kFXMTD7S9XxDBylAkLTDAPljYThiDkdiM53gg130_assertion evidence source_evidence_literature NP1244197.RABc_AJ4kFXMTD7S9XxDBylAkLTDAPljYThiDkdiM53gg130_provenance.
- NP1244197.RABc_AJ4kFXMTD7S9XxDBylAkLTDAPljYThiDkdiM53gg130_assertion SIO_000772 25467940 NP1244197.RABc_AJ4kFXMTD7S9XxDBylAkLTDAPljYThiDkdiM53gg130_provenance.
- NP1244197.RABc_AJ4kFXMTD7S9XxDBylAkLTDAPljYThiDkdiM53gg130_assertion wasDerivedFrom befree-2016 NP1244197.RABc_AJ4kFXMTD7S9XxDBylAkLTDAPljYThiDkdiM53gg130_provenance.
- NP1244197.RABc_AJ4kFXMTD7S9XxDBylAkLTDAPljYThiDkdiM53gg130_assertion wasGeneratedBy ECO_0000203 NP1244197.RABc_AJ4kFXMTD7S9XxDBylAkLTDAPljYThiDkdiM53gg130_provenance.